Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market Report 2026

Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market Overview

• Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning market size has reached to $1.61 billion in 2025 • Expected to grow to $4.57 billion in 2030 at a compound annual growth rate (CAGR) of 23.1% • Growth Driver: Rising Prevalence Of Respiratory Diseases Driving The Market Growth Due To Increasing Need For Advanced Ventilation Management • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market?

Artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning refers to the use of AI-driven algorithms to support the process of gradually reducing and ultimately discontinuing mechanical ventilation in critically ill patients. It leverages real-time patient data to predict readiness for weaning, optimize ventilator settings, and minimize complications. The approach aims to improve patient outcomes, shorten ventilation duration, and reduce ICU-related risks. The main components of artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning are software, hardware, and services. Software is a set of programs and algorithms that enable computers to perform tasks, analyze data, and provide actionable insights. They are deployed through various modes, including on-premises and cloud-based. They are used for various applications, including adult intensive care units (ICU), pediatric intensive care units (ICU), and neonatal intensive care units (ICU), and are used by various end-users, including hospitals, specialty clinics, ambulatory surgical centers, and others.

What Is The Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market Growth Forecast?

The artificial intelligence (ai)-enhanced intensive care unit (icu) ventilation weaning market size is expected to see exponential growth in the next few years. It will grow to $4.57 billion in 2030 at a compound annual growth rate (CAGR) of 23.1%. The growth in the forecast period can be attributed to increasing adoption of ai-driven critical care solutions, rising demand for outcome-based icu management, expansion of smart ventilator ecosystems, growing integration of predictive analytics in intensive care, increasing focus on reducing icu length of stay. Major trends in the forecast period include increasing use of predictive weaning algorithms, rising integration of real-time ventilator analytics, growing adoption of AI-assisted icu decision support, expansion of automated ventilation management, enhanced focus on reducing ventilation duration.

What Are The Drivers Of The Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market?

The rising prevalence of respiratory diseases is expected to propel the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market going forward. Respiratory diseases are medical conditions that affect the lungs and airways, impairing normal breathing and oxygen exchange in the body. The prevalence of respiratory diseases is rising due to aging populations in developed nations, as older adults are significantly more susceptible to chronic respiratory conditions because of weakened immune systems and cumulative environmental exposures. Artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning supports the management of respiratory diseases by continuously analyzing patient-specific data, predicting optimal weaning times, reducing the duration of mechanical ventilation, minimizing complications, and enabling personalized, efficient, and timely clinical interventions that improve patient outcomes. For instance, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, chronic obstructive pulmonary disease (COPD) accounted for 3.6% of Australia’s total disease burden and represented 50% of the overall burden from respiratory conditions. Therefore, the rising prevalence of respiratory diseases is driving the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning industry. The growing emphasis on personalized medicine is expected to propel the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market going forward. Precision medicine is a medical approach that tailor’s treatment and healthcare decisions to individual patients based on their genetic makeup, lifestyle, and environmental factors. The emphasis on personalized medicine is rising due to advancements in genomic technologies and data analytics that enable more precise and individualized patient care across critical healthcare settings. AI-enhanced ventilation weaning systems support personalized medicine by analyzing individual patient data to determine optimal timing for mechanical ventilation removal, thereby improving patient outcomes through customized treatment protocols. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022, reflecting an increase of 10 new personalized treatment approvals. Therefore, the growing emphasis on personalized medicine is driving the growth of the artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning industry.

Key Players In The Global Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market

Major companies operating in the artificial intelligence (AI)-enhanced intensive care unit (icu) ventilation weaning market are Medtronic plc, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Hamilton Medical AG, Hicuity Health Inc., Etiometry Inc., Clew Medical Ltd., Ambient Clinical Analytics Inc., ResMed Inc., Vyaire Medical, Inc., Mindray Medical International Limited, Zoll Medical Corporation, Baxter International Inc., Siemens Healthineers AG, Smiths Medical (ICU Medical, Inc.), Masimo Corporation, Aeonmed, Timpel S.A

What Are Latest Mergers And Acquisitions In The Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market?

In October 2025, Etiometry Inc., a US-based software company that specializes in providing AI-enhanced solutions to support ventilator weaning in the intensive care unit (ICU), partnered with Hospinorm FZCO to introduce its AI-driven platform to enhance critical care in the UAE. With this partnership, Hospinorm and Etiometry aim to bring AI-driven, FDA-cleared clinical decision-support technology to the UAE, empowering clinicians with real-time insights, improving patient outcomes, and elevating critical care standards across the region by enabling early detection of patient deterioration, standardizing care protocols, and optimizing resource utilization in intensive care units. Hospinorm FZCO is a UAE-based healthcare technology company that specializes in providing advanced medical solutions and innovative healthcare technologies.

What Defines the Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market?

The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market consists of revenues earned by entities by providing services such as clinician decision support systems, remote monitoring and tele-ICU services, predictive analytics and risk assessment, workflow optimization solutions, training and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced intensive care unit (ICU) ventilation weaning market also includes sales of ventilator monitoring systems, telerobotic ventilator controllers, and wearable respiratory sensors, and non-invasive ventilation (NIV) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Artificial Intelligence (AI)-Enhanced Intensive Care Unit (ICU) Ventilation Weaning Market Report 2026?

The artificial intelligence (ai)-enhanced intensive care unit (icu) ventilation weaning market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (ai)-enhanced intensive care unit (icu) ventilation weaning industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.